is usually indicated as soluble CD40L. 9, 10 Several reports point to a key role of platelet CD40L in atherosclerosis and atherothrombosis. Patients with (re)current cardiovascular disease often show increased levels of circulating soluble CD40L, predominantly originating from platelets. 11, 12 In mouse models, deficiency in Apoe or Ldlr leads to elevation of plasma lipids and predisposes for atherosclerosis. In these atherogenic mice, we and others have reported that additional deficiency in CD40L (Cd40lg −/− ) or CD40 (Cd40 −/− ) markedly impairs plaque development. 13, 14 Furthermore, we have shown that the injection of activated Cd40lg −/− platelets to Apoe −/− mice suppresses platelet-leukocyte aggregate formation, subsequent inflammation, and the platelet-dependent progression of atherosclerosis. [15] [16] [17] The CD40L-CD40 axis may also play a role in the crosstalk of platelets themselves, and thus contribute to the stability of platelet thrombi. For instance, in mice deficiency in either CD40L or CD40 was found to protect against microvascular thrombosis when the animals were challenged by lipopolysaccharide. 7 Other studies have suggested a mechanism, in which CD40L interacts with CD40-TRAF2 and stimulates the classical nuclear factor (NF) κB pathway in platelets. 18, 19 In agreement with this postulation, pharmacological inhibition of NFκB was shown to suppress platelet activation. 20 However, some reports indicate that the cleaved CD40L can interact with a different counter-receptor in both mouse and human platelets, namely the integrin β 3 chain. 21, 22 The binding of CD40L can support α IIb β 3 -dependent activation processes that have been implicated in thrombus stability.
In this article, we aimed to unravel the roles and the underlying signaling pathways of CD40L and CD40 in platelet activation and thrombus formation under conditions relevant for atherothrombosis. For this purpose, we used blood from Apoe −/− mice also deficient in CD40 or CD40L, prone to atherosclerosis, to investigate the activation pathways of platelets stimulated by collagen or plaque tissue via the GPVI receptor.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
To compare the roles of platelet CD40 and CD40L under conditions relevant for atherosclerosis and atherothrombosis, we used Apoe −/− mice with high plasma lipid levels and prone to atherosclerosis. 23 Platelets were isolated from Apoe −/− , Cd40 −/− Apoe −/− , and Cd40lg −/− Apoe −/− mice, and stimulated with key receptor agonists, that is, convulxin activating the collagen receptor GPVI, 24 ADP as an agonist stimulating the P2Y 1 /P2Y 12 receptors, and thrombin stimulating the PAR3/4 receptors. 5 Platelet activation properties were compared by flow cytometry. Deficiency in CD40 led to increased integrin α IIb β 3 activation (measured with PE-JON/A monoclonal antibody) and increased α-granule secretion (measured with FITC (fluorescein isothiocyanate)-labeled anti-P-selectin monoclonal antibody), when the platelets were stimulated with a low or high dose of convulxin ( Figure 1A and 1B) . In marked contrast, deficiency in CD40L led to reduced α IIb β 3 activation and α-granule secretion after stimulation with convulxin. Responses triggered by thrombin or ADP were not changed in the CD40-or CD40L-deficient platelets. Thrombin, as a strong agonist, showed a rather steep dose-response curve with substantial integrin activation and P-selectin expression already at 0.25 nmol/L. At lower thrombin doses, these responses became highly variable (not shown). Stimulation with ADP resulted in high α IIb β 3 activation, but not in α-granule secretion, as previously demonstrated. 25 Taken together, these results suggest that, in Apoe −/− mice, platelet CD40L and CD40 play nonidentical roles in GPVI-induced integrin activation and α-granule secretion.
Earlier experiments have demonstrated a primary role of GPVI in platelet adhesion and thrombus formation on plaque tissue or collagen at arterial flow conditions. 2, 3 We used this method of in vitro thrombus formation to investigate the roles of CD40 and CD40L in Apoe −/− mice prone to develop atherosclerosis. Therefore, blood from Apoe −/− , Cd40 −/− Apoe −/− , or Cd40lg −/− Apoe −/− mice was perfused over murine plaque material at high wall shear rate, and the thrombi formed were analyzed by brightfield and fluorescence microscopy ( Figure 2A ). Image analysis gave for each genotype a similar deposition of platelets on plaque material ( Figure 2B ), albeit the overall size of platelet aggregates was smaller in the absence of CD40 or CD40L ( Figure 2C ). Whereas P-selectin expression was similar for all genotypes, phosphatidylserine exposure (indicating procoagulant activity) was significantly reduced for Blood perfusion over collagen gave comparable results: whereas platelet deposition was similar for each genotype, the build-up of large thrombi was consistently diminished in the absence of CD40L. This difference seemed most clearly from the area covered by multilayered aggregates, which was significantly lowered in the absence of CD40L, but not in the absence of CD40 ( Figure IA -IC in the online-only Data Supplement). Again, phosphatidylserine exposure was reduced in the absence of CD40 or CD40L, whereas P-selectin expression was unaltered ( Figure ID and IE in the online-only Data Supplement).
To determine the ability of cleaved CD40L to support thrombus formation, blood samples from Apoe −/− , Cd40 −/− Apoe −/− , or Cd40lg −/− Apoe −/− mice were preincubated with CD40L peptide before the perfusion. For all genotypes, this resulted in a substantial increase in thrombus formation on plaque material ( Figure 2A ) and on collagen ( Figure IA in the online-only Data Supplement). Quantification learned that in the presence of CD40L peptide larger platelet aggregates were formed on plaque material ( Figure 2C ), which were best detected as Figure 1F in the onlineonly Data Supplement), regardless of the genotype, that is, also with platelets deficient in CD40 or CD40L. Expression of P-selectin and phosphatidylserine exposure were not affected by the CD40L preincubation (not shown). Further experiments using blood from Apoe −/− mice indicated that preincubation of the blood with a blocking antibody against CD40L caused a reduction in the formation of multilayered aggregates showing less α IIb β 3 activation, thus indicating a role of autologous CD40L in the thrombus growth ( Figure II in the online-only Data Supplement).
Other authors have reported a stimulating effect of the cleaved CD40L on platelet aggregation in response to low doses of agonists. 18, 19 To investigate this in more detail, we examined this in Apoe −/− mouse platelets also deficient in CD40L or CD40. Using platelets from Apoe −/− , Cd40 −/− Apoe −/− , or Cd40lg −/− Apoe −/− mice, a low collagen dose (0.5 μg/mL) did not result in appreciable aggregation nor shape change, whereas a high dose (5 μg/mL) induced maximal aggregation for all genotypes ( Figure 3A and 3B). Although exogenous CD40L alone was without effect, together with low collagen it caused near-maximal aggregation in all genotypes, including in platelets from the CD40-deficient mice. Taken together, these data point to a role of (cleaved) CD40L acting at least in part independently of CD40. In pilot experiments, we considered the possible involvement of another TNFR-TNF axis, that is, of the LIGHT receptor (TNFR-SF14) and LIGHT (TNF-SF14), which were reported to be present in platelets. 26 However, a blocking antibody against this receptor was unable to inhibit the enhancement by CD40L of platelet responses (not shown).
Considering the major role of the PI3K/Akt signaling pathway in integrin activation, 27 we compared the ability of collagen to induce phosphorylation at Ser 473 of Akt in platelets from the CD40-and CD40L-deficient mice. The low dose of collagen (0.5 μg/mL) not causing platelet aggregation was also unable to stimulate Akt phosphorylation, whereas the high collagen dose (5 μg/mL) led to an increased phosphorylation by 4 to 6 times ( Figure 3C ). Markedly, this collagen-induced phosphorylation of Akt was diminished in Cd40lg −/− Apoe −/− platelets and tended to be lower in Cd40 −/− Apoe −/− , when compared with Apoe −/− platelets ( Figure 3D ). Addition of CD40L alone did not evoke Akt phosphorylation (not shown), but in combination with low collagen, it caused a similar increase in phosphorylation in platelets from all genotypes ( Figure 3C ). Given that this phosphorylation is a prerequisite for integrin activation, 28, 29 these results suggest a key signaling role of PI3K-β in the stimulating effect of CD40L on collageninduced platelet aggregation.
To further study the involvement of PI3K in CD40Ldependent platelet responses, we performed aggregation experiments with platelets from Pik3cb R/R mice, expressing a catalytically inactive K 805 R mutant of PI3K-β, that is, an isoform that has previously been shown to control collagen-dependent signaling events. 30 When stimulated with high collagen, the aggregation of Pik3cb R/R platelets was considerably reduced but not annulled ( Figure 4A ), which is in agreement with published results. 31 With low collagen, exogenous CD40L failed to enhance the aggregation of Pik3cb R/R platelets, in contrast to the large effect of CD40L seen with wildtype (Pik3cb WT/WT ) platelets ( Figure 4A and 4B) . Markedly, CD40L was also unable to stimulate Akt phosphorylation in Pik3cb R/R platelets ( Figure 4C ). Additional confirmation for a role of PI3K-β came from the observation that the PI3K-βspecific inhibitor, TGX-221, abolished the stimulating effect of CD40L on collagen-induced aggregation ( Figure III Perfusion experiments were subsequently performed with blood from Pik3cb R/R and Pik3cb WT/WT mice over a collagen surface. In case of Pik3cb R/R blood, the thrombi consisted of much smaller platelet aggregates, when compared with the wild-type ( Figure IV in the online-only Data Supplement). For Pik3cb R/R thrombi, P-selectin expression was unchanged, whereas phosphatidylserine exposure was reduced. Notably, addition of CD40L to blood samples increased the size of platelet aggregates for wild-type, but not Pik3cb R/R mice. Confirming experiments were performed in the presence of TGX-221. When TGX-221-treated Apoe −/− blood, was flowed over collagen or plaque material, this resulted in thrombi with smaller platelet aggregates and reduced phosphatidylserine exposure ( Figure V in the online-only Data Supplement).
Largely based on pharmacological evidence, a role has been proposed for NFκB pathways in CD40L-and CD40dependent platelet responses. 19 To take this further, we first studied effects of the NFκB inhibitor Ro-106-9920 (2.5-25 μmol/L, targeting I-κBα) and IκB kinase (IKK) inhibitor VII (0.1-10 μmol/L, targeting IKKβ) on mouse platelet aggregation. Markedly, either compound caused a similar degree of inhibition on the aggregation responses induced by collagen alone or by collagen plus CD40L (data not shown). Because these compounds also suppressed thrombin-and collageninduced calcium responses, we suspected off-target effects. For the I-κBα inhibitor BAY 11-7082, an alternative mode of action in platelets has already been shown. 32 In nucleated cells, CD40 ligation is known to trigger several pathways leading to activation of NFκB. 33 The noncanonical pathway proceeds via phosphorylation of the regulatory protein IKKα, which relieves the default inhibition of κB kinase (p100) to induce signaling downstream of NFκB. 34 To evaluate a contribution of this pathway in CD40L-mediated platelet activation, we used Chuk1 A/A Apoe −/− mice, which are homozygous for an activation-resistant mutation of IKKα. 35 Markedly, in platelets from IKKα-deficient mice, the ability of CD40L to enhance aggregation was not affected ( Figure 5A ). Flow studies further indicated that the size of platelet aggregates on collagen was not different for control Apoe −/− and Chuk1 AA Apoe −/− blood ( Figure 5B-5D) . Surprisingly, phosphatidylserine exposure was increased in thrombi from Chuk1 AA Apoe −/− mice ( Figure 5E ). Together, these results indicate that the stimulatory effect of CD40L on thrombus growth is not mediated via the IKKα pathway to NFκB.
Discussion
The glycoproteins CD40L and CD40 play major roles in autoimmune and inflammatory reactions mediated by T-cells, endothelial cells, and leukocytes, by stimulating signaling toward NFκB activation. 36, 37 For the CD40L-CD40 dyad, involvement has been reported of the noncanonical and canonical NFκB pathways. 33 Cross-talk of CD40L and CD40 has also been shown for platelet-leukocyte and platelet-endothelial cell interactions and, as such implicated in the progression of mouse atherosclerosis 13, 15, 38 and neointima formation. 16 Figure 4 . Enhancing role of CD40L in collagen-induced platelet aggregation and Akt phosphorylation via PI3K-β. Washed platelets from Pik3cb R/R or corresponding wildtype mice (Pik3cb WT/WT ) were activated with collagen (coll, 0.5-5 μg/mL), as described in Figure 3 Here, we investigated the importance of the CD40L-CD40 axis for establishment of platelet-platelet interactions using mice with an atherogenic Apoe −/− background, that is, conditions where these platelet glycoproteins are considered to contribute to plaque progression. Our data indicate that CD40L and CD40 have, in part, different roles in platelet aggregation and thrombus growth.
In studies of whole blood thrombus formation on plaque material or collagen, in which platelet adhesion and activation are known to be triggered by GPVI, 2,39 we found that deficiency in CD40L or CD40 (not significant with collagen) impaired the formation of large, multilayered platelet aggregates. This reduced thrombus growth did not coincide with altered α-granule secretion (P-selectin expression), but was accompanied by reduced phosphatidylserine exposure, an event that also is mediated by the collagen receptor GPVI. 24 In accordance with these findings, others have reported that deficiency of CD40L alone (no Apoe −/− ) leads to reduced arterial thrombus formation in vivo. 21 In earlier work, we have found that deficiency of CD40 alone causes a small, insignificant reduction in platelet deposition on collagen. 16 Together, these results point to a moderate contribution of CD40L and CD40 in collagen-dependent thrombus growth.
Flow cytometric studies gave, in part, similar results. When triggered with the GPVI agonist convulxin, platelets from Apoe −/− mice lacking CD40L showed a reduced inte grin activation and secretion. However, platelets lacking CD40 responded by a higher integrin activation and higher P-selectin expression. The apparent different response of Cd40 −/− Apoe −/− platelets, when compared with the measurement of thrombus formation, can be explained by the fact that in flow cytometry all platelets become activated by the added GPVI agonist, whereas during thrombus formation only those platelets in direct contact with the collagen are activated via GPVI and the other platelets respond to paracrine agents. 5, 40 Hence, it seems that in thrombus-forming experiments the apparent gain-of-function of Cd40 −/− Apoe −/− platelets is overruled by non-GPVI-mediated secondary processes.
The dissociation seen in flow cytometry between the phenotypes of CD40L or CD40 deficiency is one indication for, in part, dissimilar roles of platelets CD40L and CD40. Further confirmation for a role of CD40L independently of CD40 in platelet-platelet interactions comes from (1) the observed thrombus-reducing effect by blocking CD40L, and (2) the enhanced platelet aggregation and thrombus formation noticed by supplementation of CD40L even for Cd40 −/− Apoe −/− platelets lacking CD40. Hence, we could not reproduce the finding from others that knockout of CD40 abolishes CD40Ldependent platelet aggregation. 18 The reason for this difference remains unclear. Taken together, our data imply that, in the stimulating platelet aggregation and thrombus growth, CD40L acts as least, in part, independently of CD40.
Another novel finding is the role of PI3K-β (using deficient mice and inhibitor TGX-221) and its downstream target Akt (based on Ser 473 phosphorylation) in the enhancing effect of CD40L on collagen-induced platelet aggregation and thrombus formation. This role of PI3K-β is in good agreement with the literature, demonstrating that this kinase is a major regulator of Akt phosphorylation and downstream integrin activation in response to various platelet agonists. 31, [41] [42] [43] Other authors have suggested that CD40L in platelets signals via p38 mitogen-activated protein kinase, 19 or via tyrosine phosphorylation of the integrin β 3 chain. 22 These pathways may coexist and help to support the establishment of platelet-platelet interactions. Of interest, a comparable signaling pathway, involving PI3K and Akt, has been proposed for endothelial cells, but in this case elicited by CD40 and leading to NFκB activation. 37 The unchanged collagen-induced aggregation and thrombus formation with Apoe −/− platelets deficient in IKKα activity (Chuk1 A/A ), as well as the unchanged ability of CD40L to stimulate aggregation of these platelets, points to a no more than minor role of the noncanonical IKKα/NFκB pathway-whether or not triggered via CD40-in platelet-platelet interactions. In this respect, we like to note that evidence for a role of the NFκB pathway in CD40-dependent platelet function is largely based on the use of pharmacological inhibitors. 19 We suspect that at least some of these inhibitors have effects on platelet responses (eg, Ca 2+ signaling), that are not mediated via NFκB. However, several reports using IKKβ knockout mice point to a regulatory role of the canonical NFκB pathway in platelet secretion and glycoprotein shedding. 44, 45 Hence, we cannot rule out a role for this IKKβ/NFκB pathway in platelet activation responses evoked by CD40L independently of CD40.
Interestingly, in studying thrombus formation, we observed an increase in phosphatidylserine exposure of Chuk1 AA Apoe −/− platelets, which we consider as further evidence that the IKKα/ NFκB pathway does not contribute to the role of CD40L. A mechanistic explanation for this unexpected finding is beyond the scope of this article but, not unlikely, the platelet proteome is altered by deficiency in one of the key enzymes of the NFκB transcription factor pathway. Yet, the stimulating role of CD40L on platelet aggregation and thrombus formation seems to be retained in Chuk1 AA Apoe −/− platelets.
Reports to date indicate that the cleavage of CD40L from activated platelets proceeds relatively slow and involves the matrix metalloproteinases 2 and 9, as well as integrin α IIb β 3 . 9,10,46 Given these kinetics, our data suggest a role of both platelet-associated CD40L and cleaved CD40L in controlling thrombus growth. Taken together, we find that CD40L at least in part acting independently of CD40 is another of the (integrin-dependent) platelet-derived factors that contribute to the stable formation of large thrombi, especially under atherogenic conditions. 
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